Treating postmenopausal osteoporosis in women at increased risk of fracture – critical appraisal of bazedoxifene: a review
Peter Vestergaard, Susanna vid Streym ThomsenDepartment of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus, DenmarkAbstract: Several categories of drugs to treat osteoporosis exist in the form of bisphosphonates, strontium, parathyroid hormone, and selective estrogen receptor modu...
Saved in:
Main Authors: | Peter Vestergaard (Author), Susanna vid Streym Thomsen (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2009-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bazedoxifene for the prevention of postmenopausal osteoporosis
by: Luigi Gennari, et al.
Published: (2008) -
Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture
by: Rossini M, et al.
Published: (2013) -
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
by: Roberto Cesareo, et al.
Published: (2009) -
Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain
by: Darbà J, et al.
Published: (2013) -
Management of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combination
by: Mirkin S, et al.
Published: (2013)